Search

Displaying results 3881 - 3890 of 5451 in total
  1. Drug

    Leukotriene C4

    go.drugbank.com/drugs/DB08855
    Experimental

    It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. … It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some vascular smooth muscle. (From Dictionary of Prostaglandins and Related Compounds, 1990)

    Synonyms: (R-(R*,S*-(E,E,Z,Z)))-N-(S-(1-(4-Carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-N-L-gamma-glutamyl-L-cysteinyl)glycine
  2. Drug

    Cenderitide

    go.drugbank.com/drugs/DB11777
    Investigational

    Cenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall.

  3. Drug

    Flutemetamol

    go.drugbank.com/drugs/DB15058
    Investigational

    Flutemetamol is under investigation in clinical trial NCT02353949 (Investigating the Clinical Consequences of Flutemetamol-PET-scanning).

  4. Drug

    Dezamizumab

    go.drugbank.com/drugs/DB15153
    Investigational

    Dezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).

  5. Drug

    Oxcarbazepine

    go.drugbank.com/drugs/DB00776
    ApprovedInvestigational

    [L8627,L8630,L8633] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood

    Products: Trileptal 150 mg, Trileptal 300 mg
  6. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    The potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity.

  7. Drug

    Borage oil

    go.drugbank.com/drugs/DB11238
    Approved

    eczema, seborrheic dermatitis, and neurodermatitis as well as other inflammatory, cardiovascular and endocrine disorders, although its clinical efficacy and long-term effects are not fully elucidated yet

  8. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    It was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342]

    Products: KANUMA® 2 MG/ML CONCENTRADO PARA SOLUCION PARA INFUSION.
  9. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    It is administered as a 1 hour intravenous infusion every 3 weeks.

    Products: SYLVANT 100 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN LİYOFİLİZE TOZ, 1 ADET, SYLVANT 400 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN LİYOFİLİZE TOZ, 1 ADET
  10. Drug

    Zenocutuzumab

    go.drugbank.com/drugs/DB15559
    ApprovedInvestigational

    [L51963] It works to attenuate aberrant cancer cell growth caused by genomic rearrangements involving the neuregulin 1 gene (NRG1), which is an oncogenic driver.